Answer
It is unknown whether daratumumab (Darzalex) passes into human breast milk; risk to newborns/infants cannot be excluded, so a decision must be made whether to discontinue/abstain from breastfeeding or discontinue Darzalex, considering breastfeeding benefits for the child and treatment benefits for the woman.
Sources for this answer
- DARZALEX 20 mg/mL concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 36Document updated
Sources checked